IntraBio is a leader in discovering, developing, and commercializing novel therapies and treatments for rare and neurodegenerative diseases with high unmet medical needs

News

Our Team

IntraBio’s team translates research into treatments that will significantly improve the lives of patients, their caregivers, and families.

IB1001 Program

IntraBio’s lead drug series, IB1000s, are a set of orally administered, modified amino acids (N-Acetyl-Leucine) characterized by a well-established safety and tolerability profile.

Publications

Details of IntraBio’s clinical studies are published in the world's leading medical journals.

IntraBio
Privacy Policy Cookies Policy ©2024 IntraBio. All rights reserved.